Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas

Evgeny Yakirevich1, Edmond Sabo, Inna Naroditsky

  • 1Department of Pathology, Carmel Medical Center and Rappaport Faculty of Medicine, Technion University, Haifa, Israel. eyakirevich@lifespan.org

Gynecologic Oncology
|October 4, 2005
PubMed
Abstract

Insights

Multidrug resistance (MDR) in ovarian cancer is linked to drug transporter proteins. P-glycoprotein (P-gp) expression is a significant predictor of poor survival and chemotherapy resistance in ovarian serous carcinoma patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Multidrug resistance (MDR) hinders effective chemotherapy for ovarian carcinoma.
  • MDR is often associated with the overexpression of drug transporters like P-glycoprotein (P-gp), multidrug resistance protein 1 (MRP1), and lung resistance protein (LRP).

Purpose of the Study:

  • To assess the prevalence and prognostic value of MDR-related proteins (P-gp, MRP1, LRP) in ovarian serous carcinomas.
  • To correlate the expression of these proteins with apoptosis-related markers (p53, bcl-2, bax).

Main Methods:

  • Immunohistochemical analysis of 60 ovarian serous carcinoma tissues.
  • Quantification of P-gp, MRP1, LRP, p53, bcl-2, and bax protein expression levels.
  • Statistical analysis including univariate and multivariate survival analyses.

Main Results:

  • High expression rates were observed for MRP1 (65%), p53 (75%), LRP (45%), bax (50%), and bcl-2 (41.7%).
  • P-gp expression showed a significant inverse correlation with patient survival (P=0.015) and was higher in chemotherapy-unresponsive tumors (P=0.009).
  • Multivariate analysis identified FIGO stage and P-gp expression as independent negative predictors of survival.

Conclusions:

  • P-glycoprotein (P-gp) expression is a potential independent prognostic factor for survival in ovarian serous carcinoma.
  • P-gp immunostaining can help differentiate between chemoresponsive and chemoresistant patient groups.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Caspases01:24

Caspases

Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside cells.